Desta Dosage/Direction for Use

Film-coated tablet: Posology: Adults and adolescents (12 years of age and over): The recommended dose of desloratadine is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient's disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.
Pediatric population: There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
The safety and efficacy of desloratadine 5 mg film-coated tablets in children below the age of 12 years have not been established.
Method of administration: Oral use.
The dose can be taken with or without food.
Syrup: Recommended Dose: Children 6 through 11 years of age: 5 ml (2.5 mg) DESTA SYRUP once a day, with or without a meal for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria.
Children 1 through 5 years of age: 2.5 ml (1.25 mg) DESTA SYRUP once a day, with or without a meal for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria.
Children 6 months through 11 months of age: 2 ml (1 mg) DESTA SYRUP once a day, with or without a meal for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria.
In adults and adolescents (12 years of age and over): 10 ml (5 mg) DESTA SYRUP once a day, with or without a meal for the relief of symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient's disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance. In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during allergen exposure periods.
Mode of Administration: May be taken without regard to meals.